Legal Strategies for Successful Business Sales & Acquisitions (With Pharmacy & Pharma Manufacturer Examples).
- Gaea Kassatly
- Dec 3, 2025
- 10 min read
Selling or buying a business is never just about a purchase price. It’s about structure, risk, people, licenses, timing, and emotions—especially in highly regulated industries like pharmacies and pharmaceutical manufacturing.
This blog post, by Gaea Kassatly Managing Attorney at GK Law Co., walks through the full life cycle of a deal: from “I might sell one day” to the wiring of funds and the chaos of closing week. Below is a practical breakdown with specific examples for pharmacies and pharma manufacturers.
Quick note: This is educational, not legal advice. Pharmacy and pharma deals are heavily regulated—always consult qualified counsel in your jurisdiction.
1. The Spectrum of Business Sales: From Simple to Sophisticated
Not all deals are created equal. Think of business sales on a spectrum:
On one end: a simple asset sale of a small local business.
On the other: a complex M&A transaction with private equity, data rooms, and a wall of advisers.
Key factors that push a deal toward the complex side:
Higher purchase price
Complicated financing
Highly regulated industry (pharmacy/pharma)
Multiple owners and investors
Depth and volume of due diligence
Pharmacy Example
Simple-ish: A single-location independent community pharmacy sells its assets (inventory, script files, furniture, fixtures) to a regional buyer.
Complex: A buyer acquires a chain of 20 specialty pharmacies operating in multiple states, with board of pharmacy, DEA, Medicaid, and PBM contracts in each state.
Pharma Manufacturer Example
Simple-ish: Asset sale of a small contract manufacturing line with limited SKUs and no direct branded portfolio.
Complex: Private equity acquires a branded pharmaceutical manufacturer with FDA-approved NDAs, global supply contracts, clinical trial obligations, and multiple manufacturing sites.
The more money, regulation, and moving pieces involved, the more the deal looks and behaves like a full-blown M&A transaction.
2. Getting “Exit Ready”: Valuation & Cleanup
Sellers often come to lawyers late in the game—but the real value is created long before the LOI.
Business Valuation
Sellers need a realistic idea of what the business is worth. Common valuation approaches:
Asset-based
Market-based
Income-based
You might see:
A full formal appraisal (expensive, used for bigger or more complex deals)
A business broker’s opinion of value (more practical for smaller sellers)
Clean Up the House Before Inviting Buyers In
Sellers should:
Clean up financials. Many owners run personal expenses through the business. Those need to be identified and backed out.
Resolve legal issues.
Open litigation
Unresolved employee disputes
Licensing or regulatory issues
Insurance claims
Organize documentation.Contracts, policies, corporate records, compliance manuals, SOPs—all of that will be requested in due diligence.
Pharmacy Example
Before marketing a community or specialty pharmacy, the seller should:
Identify any board of pharmacy investigations, DEA audits, or sanctions and resolve or disclose them.
Clean up financials where the owner has been running personal health insurance, car payments, or family cell phones through the pharmacy.
Make sure all PBM contracts, third-party payer agreements, wholesaler agreements, and 340B contracts are up to date and accessible.
Ensure perpetual inventory, controlled substance logs, and dispensing records are in order—those will be examined closely.
Pharma Manufacturer Example
An exit-ready manufacturer would:
Have clean batch records, deviation reports, complaints, and CAPA documentation ready for review.
Make sure supply agreements, quality agreements, and toll manufacturing contracts are organized.
Confirm all FDA registrations, licenses, and inspections (such as warning letters or Form 483 responses) are documented and current.
3. Letters of Intent (LOIs): Don’t Skip Them
An LOI is a preliminary, mostly non-binding roadmap that lays out the main business terms:
Purchase price and how it’s paid
Earnest money deposit (buyer “skin in the game”)
Due diligence period (e.g., 60–120 days)
Target closing date
Conditions to closing (financing, landlord consent, license transfer, etc.)
Any exclusivity / no-shop provisions
While parties are often tempted to “skip the paper and just do the deal,” we strongly advise against that.
Why LOIs matter:
They set expectations and surface deal-breakers early.
They give the lawyers a framework, so the definitive agreement can be drafted faster.
They help justify the time and cost by demonstrating mutual commitment—especially when tied to an earnest money deposit.
Pharmacy Example
A regional chain wants to buy a specialty oncology pharmacy:
LOI states that closing is contingent on:
Successful assignment of the pharmacy lease.
Approval of change of ownership by state board of pharmacy and Medicaid.
Acceptance or novation of PBM contracts and certain payer agreements.
It includes a 90-day due diligence period and a requirement that the seller not shop the deal to other buyers during that time.
Pharma Manufacturer Example
A PE fund negotiating to acquire a sterile injectables manufacturer:
LOI specifies:
Purchase price + potential earnout tied to FDA approval of a pending ANDA.
Contingency for buyer obtaining financing.
Contingency for assignment of key supply and distribution agreements and ability to continue contract manufacturing for key clients.
4. Asset Sale vs. Stock Sale: Picking the Right Structure
Two main ways to buy a business:
Asset Sale (Asset Purchase Agreement – APA) Buyer purchases specific assets (and sometimes assumes specific liabilities) of the business.
Tangible: inventory, equipment, furniture, fixtures
Intangible: IP, goodwill, customer lists, trade names, data
Think: Buyer buys what’s inside the box, not the box itself. The seller keeps the legal entity.
Stock/Share Sale (Stock/Share Purchase Agreement – SPA) Buyer acquires the legal entity itself (corporation or LLC).They step into the seller’s shoes: contracts, licenses, assets, and liabilities generally stay where they are.
Most small to mid-market deals trend toward asset sales, especially where buyers want to avoid unknown or legacy liabilities. But there are strong reasons to structure a deal as a stock sale.
When a Stock Sale Makes Sense
Key contracts are hard to transfer. Government contracts, leases with strict anti-assignment clauses, or special vendor agreements.
Licensing is tied to the entity. Where reapplying for permits or regulatory approvals would be onerous or risky.
Employee continuity. Keeping the same employer entity can reduce disruption and help key employees feel more secure.
(Still, change-of-control clauses can be triggered and may require third-party consent anyway.)
Pharmacy Example
Asset Sale: Buying a single independent pharmacy—buyer forms a new LLC and buys:
Inventory, script files, customer records, equipment, phone numbers, website.
Buyer applies for new DEA registration, state board licenses, Medicaid and PBM enrollments.
Stock Sale: Buying a long-standing mail-order pharmacy that has:
Difficult-to-obtain, multi-state licenses.
Hard-won PBM and specialty network access that may be non-assignable.The buyer may favor a stock sale to step into the existing entity and preserve those relationships, then manage any change-of-control consents as needed.
Pharma Manufacturer Example
Asset Sale: Buyer purchases a specific product line (brand + IP + equipment + inventory) from a manufacturer, but not the entire company.
Stock Sale: Buyer acquires the actual corporate entity that:
Holds FDA-approved NDAs/ANDAs.
Is the direct party to global supply and distribution agreements. Restarting those under a new entity could delay approvals or disrupt supply, so a stock sale may be preferable.
5. Structuring the Purchase Price: Cash, Notes & Earnouts
Not every seller gets paid 100% in cash at closing. Two common forms of deferred payments:
1. Seller Carryback Note (Vendor Take-Back)
Seller finances a portion of the purchase price.
Buyer signs a promissory note and pays over time, with interest.
Typically secured by:
A personal guarantee from the principals, and
A security interest in the business assets (inventory, equipment, IP, etc.).
If the buyer defaults, the seller can chase:
The individuals (under the guarantee), and
The collateral (via foreclosure on business assets).
2. Earnout
A portion of the purchase price is contingent on future performance.
Based on metrics like:
Revenue
EBITDA/profit
Customer retention
Other KPIs
Earnouts align incentives but can be contentious if the parties don’t clearly define how the metrics are calculated.
Typical Range
Carrybacks and earnouts often sit in the 20–30% range of the purchase price (though it can vary widely).
Pharmacy Example
Buyer acquires a specialty pharmacy:
Seller receives 70% in cash at closing.
15% in a seller note over 5 years, secured by inventory and receivables.
15% as an earnout based on:
Maintaining certain script volumes and payer mix.
Retaining specific hospital or clinic referral relationships.
Given reimbursement volatility and PBM pressures, both sides must be clear about how revenue and margins will be calculated.
Pharma Manufacturer Example
Buyer acquires a manufacturer with a strong pipeline:
Cash at closing for current products.
Additional earnout:
Triggered if a specific product gets FDA approval by a certain date.
Or if annual sales of a new product exceed a defined threshold.
6. Due Diligence: What Buyers Really Look At
Due diligence is the deep dive into the target business before closing. It protects both sides:
Buyer verifies what they’re buying and identifies risk.
Seller justifies the asking price and reduces post-sale surprises.
There are four main buckets:
1. Legal Due Diligence
Corporate records and ownership structure
Assignability and terms of key contracts (customers, suppliers, landlords)
Licensure and regulatory compliance
Employment agreements and independent contractor arrangements
Good standing of the entity
2. Financial Due Diligence
Typically handled by a CPA/financial adviser:
P&Ls, balance sheets, cash flow statements
Tax returns
Debt, liens, and other liabilities
Working capital needs
3. Commercial Due Diligence
Market position and competitive landscape
Customer base and concentration risk
Growth opportunities and scalability
4. Operational Due Diligence
Supply chain and vendor dependencies
Quality of management team and staff
Facilities and equipment
Technology and systems (off-the-shelf vs custom, gaps, scalability)
Pharmacy Example
Legal/operational due diligence for a pharmacy might include:
State board of pharmacy and DEA registrations, inspection histories, and any sanctions.
PDMP compliance, controlled substance dispensing policies, and logs.
PBM audits and chargebacks, recoupment risks, and pending disputes.
Payor mix, reimbursement patterns, DIR fees, and plan terminations.
Script file review: volumes, specialty lines, and prescriber concentration.
Pharma Manufacturer Example
Due diligence for a manufacturer might include:
FDA establishment registrations, inspection history (e.g., 483s, warning letters).
Batch records, deviation investigations, complaints, and CAPAs.
Validation records for equipment, processes, and cleaning.
Supply and quality agreements with API suppliers and contract customers.
IP portfolio: patents, trademarks, licenses.
7. Retaining Key Employees
Deals often succeed or fail based on whether the right people stay.
Steps:
Identify key employees. Who is critical for continuity (and in pharmacy/pharma, for licenses)?
Involve them carefully and early (when appropriate). Surprise transitions can cause panic. But you also don’t want to destabilize the whole workforce too early.
Use retention tools:
Retention/stay bonuses (paid if they remain for 12–24 months).
Equity or phantom equity for higher-level employees.
Competitive or improved compensation and benefits.
Use thoughtfully structured employment agreements, particularly in states where “at-will” employment is the default.
Pharmacy Example
Key employees may include:
Pharmacist-in-Charge (PIC) / Responsible Pharmacist
Clinical pharmacist managing specialty programs
Key pharmacy techs who run compounding, inventory, or 340B programs
A buyer may offer:
A retention bonus payable after 12–18 months.
A new employment agreement acknowledging their PIC role and compensation.
Clear communication about no immediate reductions in staff or benefits.
Pharma Manufacturer Example
Key employees may include:
Head of Quality/QA
Director of Regulatory Affairs
Plant manager and key production supervisors
Retention may involve:
Bonus tied to successful FDA inspections post-closing.
Equity interests or profit-sharing in the new ownership structure.
Commitment to maintain certain staffing and capital improvement levels.
8. Non-Competes, Non-Solicits & Confidentiality
2024’s hot topic: the FTC’s attempt to enforce a nationwide non-compete ban, including limited sale-of-business exceptions. This rule is currently enjoined in federal court and not in effect.
For now:
State law still largely governs non-competes.
Many states restrict non-competes based on salary thresholds or job type.
Sale-of-business non-competes are often treated more favorably than pure employment non-competes—but this varies.
Even where non-competes are limited, two tools remain essential:
Non-Solicitation Agreements
No poaching of customers, vendors, or employees.
Confidentiality Agreements
Protect trade secrets, customer lists, pricing, proprietary formulas, etc.
Pharmacy Example
Buyer of a specialty pharmacy may require the seller (and selling pharmacists):
Not to open another competing pharmacy within a defined radius for a certain period (to the extent enforceable under state law).
Not to solicit existing prescribers, long-term care facilities, clinics, or PBM reps.
To keep script files, pricing, and payer arrangements confidential.
Pharma Manufacturer Example
Buyer of a manufacturer may require:
Non-solicitation of contract manufacturing clients and key suppliers.
Strong confidentiality to protect formulas, process know-how, analytical methods, and regulatory strategies.
9. The Paperwork: Core Documents in a Business Sale
Key documents typically include:
Main Agreement
Asset Purchase Agreement (APA) or Stock/Share Purchase Agreement (SPA).
Contains purchase price, payment terms, conditions to closing, closing mechanics.
Representations & Warranties + Indemnification
Seller promises certain things about the business (no undisclosed liabilities, accurate financials, compliance with law, etc.).
If those promises are untrue and the buyer suffers losses, indemnification is how the buyer gets reimbursed.
Ancillary Documents
Non-compete / non-solicit / confidentiality agreements
Employment agreements for former owners or key staff
Lease assignments or new leases
Assignments of key contracts (suppliers, distributors, payors)
IP assignment agreements
Promissory note + personal guarantee + security agreement (if seller financing)
Bill of Sale (for hard assets)
UCC-1 filing (to perfect security interests)
Disclosure schedules – detailed exceptions to the reps and warranties (e.g., “except for that one employee claim,” “except for those two tax liens”)
In larger or more complex deals, these schedules can run to dozens of pages or more.
10. Closing & Post-Closing: What Happens at the Finish Line
Pre-Closing
Decide whether to use escrow (often a third-party escrow agent).
Finalize all documents and settlement statements showing exactly who pays and receives what.
Arrange wiring instructions and confirm all closing conditions (financing, consents, approvals) are met.
Most closings today are done virtually via Zoom/Teams, but some parties still prefer in-person signings.
Closing Day
Parties sign all final documents.
Funds are wired (often through escrow).
The buyer effectively gets “the keys.”
Post-Closing
True-ups: Adjustments for working capital, inventory, or other agreed metrics.
Seller provides agreed-upon transitional support (often 30 days included in the price, beyond that paid separately).
Legal and administrative changes:
Corporate records updated.
IP, trade names, trademarks transferred.
Regulatory agencies notified or COH/COA filings completed.
Pharmacy Example
Post-closing work may include:
Submitting change-of-ownership filings to the state board of pharmacy, DEA, Medicaid, and commercial payors.
Updating DEA 222 authorization, CSOS certificates, and power of attorney forms.
Notifying PBMs and 340B partners as required.
Communicating with staff and prescribers about the transition.
Pharma Manufacturer Example
Post-closing may involve:
Notifying FDA and other regulators of ownership changes as required.
Updating quality agreements and supply contracts.
Harmonizing SOPs and quality systems with the buyer’s standards.
Managing integration of IT, ERP, and batch-record systems.
Thinking About Selling or Buying a Pharmacy or Pharma Company?
Whether you’re sn owner looking toward retirement or your next venture, or a buyer (especially in healthcare and pharmacy) trying to structure a safe, scalable deal, you need a team that understands both M&A mechanics and healthcare/pharmacy regulation.
If you’re considering a sale or acquisition in this space and want help:
Getting your business “exit ready”
Structuring LOIs and purchase agreements
Navigating licensure, payor contracts, and regulatory risk
→ Reach out to schedule a consult. We’ll walk through your goals, your current structure, and your options.
